ClinicalTrials.gg
CompletedNCT03799627FO2RWARD-2Updated Sep 29, 2022Results posted

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

A Phase 2 interventional study of Vadadustat and Epoetin Alfa in Anemia and Dialysis-dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 41 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-09-29.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
11th of 27
175 · median 60
Started
2019
with 1 other
Phase 2
8 of 27
none open now
Registered
20th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 11th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 2, and was the 20th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

This is a Phase 2 open-label efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) study to evaluate oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy.

Read the detailed description

This is a Phase 2, randomized, open-label study to evaluate efficacy and safety of oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy. The study will be conducted in two parts running in parallel: Part 1, Main Study in a hemodialysis population on maintenance treatment with Epoetin Alfa; Part 2 is in a hemodialysis population that are erythropoiesis-stimulating agent (ESA) hyporesponders on maintenance treatment with Epoetin Alfa. For all participants (Main and ESA hyporesponder parallel study), the study will include a Screening Period, a Treatment Period, and a Safety Follow-Up Period. PK and PD sampling will be done throughout the study. The aim is to achieve and maintain hemoglobin (Hb) levels within the target range of 10.0 to 11.0 grams per deciliter (g/dL), inclusive, while targeting the middle of the range and minimizing excursions outside the target range.

03

Conditions studied

  • Anemia
  • Dialysis-dependent Chronic Kidney Disease

Keywords

  • Vadadustat
  • AKB-6548
  • Anemia
  • Chronic kidney disease (CKD)
  • erythropoietin
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age, providing
  • Receiving chronic, outpatient in-center hemodialysis (TIW) for end-stage renal disease for at least 12 weeks prior to Screening
  • Maintained on intravenous Epoetin Alfa therapy for 8 weeks prior to and including Screening through Screening Visit 2 (SV2)
  • Eligibility in the Main study and erythropoiesis-stimulating agent (ESA) hyporesponder parallel study is based on the following mean weekly Epoetin Alfa doses:

    1. Main study: Mean weekly Epoetin Alfa dose \<300 Units per kilogram per week (U/kg/week) for 8 weeks prior to SV2;
    2. ESA hyporesponder parallel study: Mean weekly Epoetin Alfa dose ≥300 U/kg/week for 8 weeks prior to SV2
  • Two values measured by the central laboratory at least 4 days apart between Screening Visit 1 (SV1) and SV2 as indicated:.

    1. Main study: 2 Hb values between 8.5 and 11.0 g/dL, inclusive;
    2. ESA hyporesponder parallel study: 2 Hb values between 8.0 and 10.0 grams per deciliter (g/dL), inclusive
  • Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥20% during Screening
  • Folate and vitamin B12 measurements ≥ lower limit of normal during Screening
  • Hemodialysis adequacy as indicated by single-pool Kt/Vurea ≥1.2 using the most recent historical measurement within 8 weeks prior to or during Screening
  • Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than chronic kidney disease (e.g., sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic , myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia)
  • Active bleeding or recent blood loss within 8 weeks prior to randomization
  • Red blood cell (RBC) transfusion within 8 weeks prior to randomization
  • Anticipated to discontinue hemodialysis during the study
  • Judged by the Investigator that the participant is likely to need rescue therapy (ESA administration or RBC transfusion) immediately after enrollment in the study
  • History of chronic liver disease (e.g., chronic infectious hepatitis, chronic liver disease, cirrhosis or fibrosis of the liver)
  • (AST)/serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), or total >1.5 x (ULN) during Screening. Participants with a history of Gilbert's syndrome are not excluded.
  • Current uncontrolled hypertension as determined by the Investigator that would contraindicate the use of Epoetin Alfa
  • Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure (HF) or Class IV HF, or stroke within 12 weeks prior to or during Screening
  • History of new or recurrent malignancy within 2 years prior to and during Screening or currently receiving treatment or suppressive therapy for cancer. Participants with treated basal cell carcinoma of skin, curatively resected squamous cell carcinoma of skin, or cervical carcinoma in situ are not excluded.
  • History of deep vein thrombosis or pulmonary embolism within 12 weeks prior to or during Screening
  • History of hemosiderosis or hemochromatosis
  • History of prior organ transplantation (participants with a history of failed kidney transplant or corneal transplants are not excluded)
  • Scheduled organ transplant from a living donor and participants on the kidney transplant wait-list who are expected to receive a transplant within 6 months
  • History of a prior hematopoietic stem cell or bone marrow transplant (stem cell therapy for knee arthritis is not excluded)
  • Known to Vadadustat, Epoetin Alfa, or any of their
  • Any prior use of a hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitor or any use of an medication within 30 days or 5 half-lives of the investigational medication (whichever is longer), prior to randomization
  • For female participants of non-:

    1. inability to confirm surgical sterility (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy) at least 1 month prior to Screening;
    2. not considered (no menses for >1 year with follicle stimulating hormone >40 U/Liter at Screening)
  • For female participants of childbearing potential:

    1. lack of confirmation of the use of acceptable forms of * for a minimum of one complete menstrual cycle prior to Screening;
    2. positive serum pregnancy test at SV2;
    3. unwilling to use two acceptable forms of contraception* (at least one of which must be a barrier method) starting Baseline/Day 1, throughout the Treatment Period and for 30 days after the final study drug administration
  • Breastfeeding during Screening or throughout the Treatment Period and for 30 days after the final study drug administration
  • Donation of ova starting at Screening, throughout the Treatment Period, and for 30 days after the final study drug administration
  • Male participants who have not had a vasectomy and do not agree to the following: use of an acceptable form of contraception* during the study and for 30 days after the last dose of the study drug; to not donate semen during the study and for at least 30 days after the last dose of Vadadustat
  • Participants with bilateral native nephrectomy
  • Any other reason, which in the opinion of the Investigator, would make the participant not suitable for participation in the study

    • Acceptable forms of contraception include:

      • Established use of oral, injected or implanted hormonal methods of contraception;
      • Placement of an intrauterine device or intrauterine system;
      • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Vadadustat

    The initial dose of Vadadustat (300, 450, or 600 milligrams \[mg\]) will be based upon the dose of Epoetin Alfa dose participants had received prior to Vadadustat treatment

    Drug: Vadadustat

  • Experimental
    Vadadustat TIW

    Participants randomized to Vadadustat (Main and erythropoiesis-stimulating agent \[ESA\] hyporesponder parallel studies) who complete a once-daily dosing regimen treatment period and meet eligibility criteria for transition to three times weekly (TIW) dosing will switch to TIW dosing

    Drug: Vadadustat TIW

  • Active comparator
    Epoetin Alfa

    Epoetin Alfa

    Drug: Epoetin Alfa

Interventions

  • Vadadustat Tablets 150 mg

    Also known as: AKB-6548

  • Epoetin Alfa

    Also known as: Procrit, Epogen

  • DrugVadadustat TIW

    Oral Vadadustat

06

What researchers measure

Primary outcomes

  1. Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP)

    Change from Baseline in Hb value was calculated as the PEP Hb value minus the Baseline Hb value. The PEP value was the average Hb value from Week 10 to Week 12. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1.

    Time frame: Baseline; Week 10 to Week 12

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. TEAEs, defined as AEs that began (or pre-existing AEs that worsened) on or after the first dose through each participant's last participation date, are reported.

    Time frame: Up to Week 24

  3. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

    Parameters assessed for laboratory values included hematology (excluding the primary and secondary efficacy endpoint results related to Hb), clinical chemistry, lipid profiles, and glucose. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to Week 24

  4. Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values

    Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing vital sign values for clinically significant changes.

    Time frame: Up to Week 24

  5. Number of Participants Classified as Hb Outliers

    The target range for Hb was from 10.0 to 11.0 grams per deciliter (g/dL). Hb outliers included participants with a Hb increase of more than 12.0 g/dL or \<8.0 g/dL and decline in Hb ≥0.5 g/dL from Baseline, and a Hb increase to more than 1.0 g/dL within any 2-week interval during the Study Period.

    Time frame: Weeks 13 - 20

Secondary outcomes

  1. Number of Participants With Hb Values Within the Target Range at the PEP

    The target range for Hb was from 10.0 to 11.0 g/dL, inclusive. The PEP was comprised of Week 10 to Week 12.

    Time frame: Week 10 to Week 12

  2. Mean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12

    Change from PEP was calculated as the SEP value minus the PEP value. The PEP value was the average Hb value from Week 10 to Week 12. The SEP value was the average Hb value from Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.

    Time frame: Week 10 to Week 12; Week 18 to Week 20

  3. Mean Change in Hb Between Baseline and the SEP

    Change from Baseline was calculated as the SEP value minus the Baseline value. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1. The SEP value was the average Hb value from Week 18 to Week 20.

    Time frame: Baseline; Week 18 to Week 20

  4. Number of Participants With Hb Values Within the Target Range at the SEP

    The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20.

    Time frame: Week 18 to Week 20

  5. Number of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing

    The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.

    Time frame: Week 18 to Week 20

  6. Number of Participants With a Mean Increase in Hb From Baseline to the PEP ≥0.5 g/dL or With Hb Values Within the Target Range at the PEP

    The target range for Hb was from 10.0 to 11.0 g/dL. The PEP was comprised of Week 10 to Week 12.

    Time frame: Week 10 to Week 12

  7. Number of Participants With a Mean Increase in Hb From Baseline to the SEP ≥0.5 g/dL or With Hb Values Within the Target Range at the SEP

    The target range for Hb was from 10.0 to 11.0 grams per g/dL. The SEP was comprised of Week 18 to Week 20.

    Time frame: Week 18 to Week 20

  8. Number of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation

    Iron supplementation was performed to maintain ferritin ≥200 nanograms/milliliters (ng/mL) and transferrin saturation (TSAT) ≥20%.

    Time frame: Up to Week 20

  9. Number of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue

    ESA rescue therapy was administered in participants with Hb ≥8.5 g/dL, and was stopped when Hb reached ≥9.0 g/dL.

    Time frame: Up to Week 20

  10. Number of Participants Requiring Red Blood Cell (RBC) Transfusion

    RBC transfusion was administered as rescue therapy in the event of an acute or severe loss of blood.

    Time frame: Up to Week 20

  11. Mean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group

    Blood samples were collected from participants at defined time points for the assessment of EPO concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 1 (pre-dose), Week 1 +1 (Day 8; pre-dose), Week 11 (pre-dose), and Week 13 (pre-dose)

  12. Mean Change From Baseline in Reticulocyte Count

    Blood samples were collected from participants at defined time points for the assessment of reticulocyte count. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 1, Week 4, Week 8, Week 11, Week 12, Week 13, Week 16, and Week 20

  13. Mean Change From Baseline in Iron Concentration

    Blood samples were collected from participants at defined time points for the assessment of iron indices, including iron concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20

  14. Mean Change From Baseline in Ferritin Concentration

    Blood samples were collected from participants at defined time points for the assessment of iron indices, including ferritin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20

  15. Mean Change From Baseline in Total Iron Binding Capacity

    Blood samples were collected from participants at defined time points for the assessment of iron indices, including Total Iron Binding Capacity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20

  16. Mean Change From Baseline in Hepcidin Concentration

    Blood samples were collected from participants at defined time points for the assessment of hepcidin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Week 12 and Week 20

  17. Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose

    Blood samples were collected from participants at defined time points for the assessment of Cmax of Vadadustat following a single dose.

    Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose

  18. Geometric Mean Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of Vadadustat Following a Single Dose

    Blood samples were collected from participants at defined time points for the assessment of AUC and AUC0-24 of Vadadustat following a single dose.

    Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose

  19. Median Terminal Half-life (t1/2) of Vadadustat Following a Single Dose

    Blood samples were collected from participants at defined time points for the assessment of t1/2 of Vadadustat following a single dose.

    Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose

  20. Median Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose

    Blood samples were collected from participants at defined time points for the assessment of Tmax of Vadadustat following a single dose.

    Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose

  21. Geometric Mean Elimination Rate Constant (λz) of Vadadustat Following a Single Dose

    Blood samples were collected from participants at defined time points for the assessment of λz of Vadadustat following a single dose.

    Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose

  22. Geometric Mean Apparent Total Body Clearance (CLss/F) of Vadadustat Following a Single Dose

    Blood samples were collected from participants at defined time points for the assessment of CLss/F of Vadadustat following a single dose.

    Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose

  23. Geometric Mean Apparent Volume of Distribution (Vz/F) of Vadadustat Following a Single Dose

    Blood samples were collected from participants at defined time points for the assessment of Vz/F of Vadadustat following a single dose.

    Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose

07

Results

Posted Sep 29, 2022
Limitations and caveats
Conclusions were drawn from results of the Main Study (n=165). As the sample size in the Erythropoiesis-stimulating Agent (ESA) Hyporesponder Parallel Study (n=10) was small in both the Vadadustat and Epoetin Alfa treatment groups, these results did not allow to meaningful interpretation of the data.

Participant flow

Participant flow — Overall Study
MilestoneLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Started3534231821211355
Completed27232281281032
Not completed811110913323
Withdrew: Adverse event120025020
Withdrew: Physician decision220022000
Withdrew: Withdrawal by subject110203000
Withdrew: Lack of efficacy000100000
Withdrew: Lost to follow-up000000101
Withdrew: Death000100000
Withdrew: Study drug put on hold100000000
Withdrew: Due to urgent safety measures letter120210000
Withdrew: Kidney transplantation100110000
Withdrew: Participant was on rescue epogen010000101
Withdrew: Placed on dose hold until end of treatment010000000
Withdrew: Met exclusion criteria000100000
Withdrew: Investigational product noncompliance000100000
Withdrew: Participant relocation000101000
Withdrew: Eurofin issue000010000
Withdrew: Noncompliance with site instructions000010000
Withdrew: Participant's last dose prior to end of treatment000010000
Withdrew: Changes in hemoglobin values121002101

Outcome measures

PrimaryMean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP)

Change from Baseline in Hb value was calculated as the PEP Hb value minus the Baseline Hb value. The PEP value was the average Hb value from Week 10 to Week 12. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1.

Time frame:
Baseline; Week 10 to Week 12
Reported as:
Mean · grams per deciliter (g/dL)
Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP)
grams per deciliter (g/dL)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Baseline10.223 ± 0.580510.059 ± 0.676910.165 ± 0.68069.778 ± 0.683210.288 ± 0.544510.095 ± 0.71509.950 ± 0.79509.530 ± 0.28649.620 ± 0.6925
Change from Baseline at PEP-0.371 ± 0.89200.072 ± 1.13530.160 ± 0.7519-0.911 ± 1.3515-0.284 ± 1.0383-0.418 ± 1.27520.268 ± 1.0087-0.671 ± 0.7643-0.290 ± 1.7730
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. TEAEs, defined as AEs that began (or pre-existing AEs that worsened) on or after the first dose through each participant's last participation date, are reported.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants With Treatment-emergent Adverse Events (TEAEs)182713121413953
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

Parameters assessed for laboratory values included hematology (excluding the primary and secondary efficacy endpoint results related to Hb), clinical chemistry, lipid profiles, and glucose. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values000000000
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Sign Values

Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing vital sign values for clinically significant changes.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values000000000
PrimaryNumber of Participants Classified as Hb Outliers

The target range for Hb was from 10.0 to 11.0 grams per deciliter (g/dL). Hb outliers included participants with a Hb increase of more than 12.0 g/dL or \<8.0 g/dL and decline in Hb ≥0.5 g/dL from Baseline, and a Hb increase to more than 1.0 g/dL within any 2-week interval during the Study Period.

Time frame:
Weeks 13 - 20
Reported as:
Count of participants · Participants
Number of Participants Classified as Hb Outliers
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Hb >12.0 g/dL223010100
Hb >13.0 g/dL101000000
Hb >14.0 g/dL101000000
Hb <8.0 g/dL and decline in Hb ≥0.5 g/dL from Baseline220113111
Hb increase >1.0 g/dL within any 2-week interval484423602
SecondaryNumber of Participants With Hb Values Within the Target Range at the PEP

The target range for Hb was from 10.0 to 11.0 g/dL, inclusive. The PEP was comprised of Week 10 to Week 12.

Time frame:
Week 10 to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Hb Values Within the Target Range at the PEP
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants With Hb Values Within the Target Range at the PEP121315144600
SecondaryMean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12

Change from PEP was calculated as the SEP value minus the PEP value. The PEP value was the average Hb value from Week 10 to Week 12. The SEP value was the average Hb value from Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.

Time frame:
Week 10 to Week 12; Week 18 to Week 20
Reported as:
Mean · g/dL
Mean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12
g/dLVadadustat 300 mg (Starting Dose in TIW Dosing Regimen)Vadadustat 450 mg (Starting Dose in TIW Dosing Regimen)Vadadustat 600 mg (Starting Dose in TIW Dosing Regimen)Vadadustat 750 mg (Starting Dose in TIW Dosing Regimen)Vadadustat Total (TIW Dosing Regimen)ESA Hyporesponder Parallel Study: Vadadustat ≤ 750 mg (TIW Dosing Regimen)
Mean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12-0.050 ± NA-1.021 ± 1.0961-0.360 ± 0.4894-0.103 ± 1.9225-0.422 ± 1.1708—
SecondaryMean Change in Hb Between Baseline and the SEP

Change from Baseline was calculated as the SEP value minus the Baseline value. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1. The SEP value was the average Hb value from Week 18 to Week 20.

Time frame:
Baseline; Week 18 to Week 20
Reported as:
Mean · g/dL
Mean Change in Hb Between Baseline and the SEP
g/dLLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Mean Change in Hb Between Baseline and the SEP-0.197 ± 1.1597-0.186 ± 0.87030.070 ± 0.95450.114 ± 1.0242-0.421 ± 0.8370-0.545 ± 0.97710.343 ± 0.8897-0.283 ± 0.7371-0.400 ± 1.0157
SecondaryNumber of Participants With Hb Values Within the Target Range at the SEP

The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20.

Time frame:
Week 18 to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Hb Values Within the Target Range at the SEP
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants With Hb Values Within the Target Range at the SEP679232611
SecondaryNumber of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing

The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.

Time frame:
Week 18 to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing
ParticipantsVadadustat 300 mg (Starting Dose in TIW Dosing Regimen)Vadadustat 450 mg (Starting Dose in TIW Dosing Regimen)Vadadustat 600 mg (Starting Dose in TIW Dosing Regimen)Vadadustat 750 mg (Starting Dose in TIW Dosing Regimen)Vadadustat Total (TIW Dosing Regimen)ESA Hyporesponder Parallel Study: Vadadustat ≤ 750 mg (TIW Dosing Regimen)
Number of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing02237—
SecondaryNumber of Participants With a Mean Increase in Hb From Baseline to the PEP ≥0.5 g/dL or With Hb Values Within the Target Range at the PEP

The target range for Hb was from 10.0 to 11.0 g/dL. The PEP was comprised of Week 10 to Week 12.

Time frame:
Week 10 to Week 12
Reported as:
Count of participants · Participants
Number of Participants With a Mean Increase in Hb From Baseline to the PEP ≥0.5 g/dL or With Hb Values Within the Target Range at the PEP
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants With a Mean Increase in Hb From Baseline to the PEP ≥0.5 g/dL or With Hb Values Within the Target Range at the PEP141918166801
SecondaryNumber of Participants With a Mean Increase in Hb From Baseline to the SEP ≥0.5 g/dL or With Hb Values Within the Target Range at the SEP

The target range for Hb was from 10.0 to 11.0 grams per g/dL. The SEP was comprised of Week 18 to Week 20.

Time frame:
Week 18 to Week 20
Reported as:
Count of participants · Participants
Number of Participants With a Mean Increase in Hb From Baseline to the SEP ≥0.5 g/dL or With Hb Values Within the Target Range at the SEP
ParticipantsStratum 1 (Epoetin Alfa ≤90 U/kg/Week): Vadadustat 300 mgStratum 1 (Epoetin Alfa ≤90 U/kg/Week): Vadadustat 450 mgStratum 1 (Epoetin Alfa ≤90 U/kg/Week): Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder (Epoetin Alfa ≥300 U/kg/Week): Vadadustat 600 mgESA Hyporesponder (Epoetin Alfa ≥300 U/kg/Week): Epoetin Alfa
Number of Participants With a Mean Increase in Hb From Baseline to the SEP ≥0.5 g/dL or With Hb Values Within the Target Range at the SEP101114352812
SecondaryNumber of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation

Iron supplementation was performed to maintain ferritin ≥200 nanograms/milliliters (ng/mL) and transferrin saturation (TSAT) ≥20%.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation2321161014181045
SecondaryNumber of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue

ESA rescue therapy was administered in participants with Hb ≥8.5 g/dL, and was stopped when Hb reached ≥9.0 g/dL.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue283553131
SecondaryNumber of Participants Requiring Red Blood Cell (RBC) Transfusion

RBC transfusion was administered as rescue therapy in the event of an acute or severe loss of blood.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants Requiring Red Blood Cell (RBC) Transfusion
ParticipantsLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Number of Participants Requiring Red Blood Cell (RBC) Transfusion010312011
SecondaryMean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group

Blood samples were collected from participants at defined time points for the assessment of EPO concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 1 (pre-dose), Week 1 +1 (Day 8; pre-dose), Week 11 (pre-dose), and Week 13 (pre-dose)
Reported as:
Geometric mean · Milliunits per milliliter
Mean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group
Milliunits per milliliterLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgESA Hyporesponder: Vadadustat 600 mg
Baseline7.33 ± 57.39.53 ± 54.09.93 ± 83.68.77 ± 48.26.98 ± 61.68.03 ± 53.2
Week 112.1 ± 94.317.5 ± 97.015.3 ± 72.614.1 ± 86.420.2 ± 90.812.9 ± 54.2
Week 1 +1 (Day 8)15.6 ± 76.318.9 ± 98.216.1 ± 76.018.0 ± 49.817.4 ± 104.89.49 ± 37.1
Week 1114.2 ± 55.914.9 ± 106.219.4 ± 78.020.6 ± 169.617.3 ± 53.4—
Week 13—15.7 ± 107.239.2 ± NA—10.5 ± 47.1—
SecondaryMean Change From Baseline in Reticulocyte Count

Blood samples were collected from participants at defined time points for the assessment of reticulocyte count. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 1, Week 4, Week 8, Week 11, Week 12, Week 13, Week 16, and Week 20
Reported as:
Mean · 10^3 cells/microliter (µL)
Mean Change From Baseline in Reticulocyte Count
10^3 cells/microliter (µL)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Baseline51.9 ± 27.5747.2 ± 17.8148.8 ± 27.2759.3 ± 42.0248.4 ± 33.4551.5 ± 25.1462.6 ± 25.8877.6 ± 51.0483.0 ± 45.34
Week 13.1 ± 24.096.9 ± 30.601.0 ± 22.42-18.1 ± 24.81-3.9 ± 28.51-6.6 ± 33.8020.4 ± 48.64-35.8 ± 45.06-25.2 ± 29.73
Week 414.6 ± 32.2514.9 ± 29.450.8 ± 40.68-5.6 ± 37.382.9 ± 39.686.1 ± 33.2422.5 ± 50.53-26.8 ± 55.4417.5 ± 26.21
Week 814.0 ± 31.4023.9 ± 39.2623.1 ± 38.989.1 ± 46.3820.4 ± 49.4223.1 ± 20.3314.0 ± 54.60-3.3 ± 67.56-21.8 ± 69.36
Week 1111.7 ± 25.0620.2 ± 25.8021.0 ± 35.1226.2 ± 26.232.5 ± 70.429.2 ± 41.303.9 ± 46.15-6.7 ± 76.89-27.2 ± 71.36
Week 1216.1 ± 32.6016.3 ± 34.2722.2 ± 26.7247.7 ± 66.6620.3 ± 44.3026.9 ± 52.644.6 ± 39.533.8 ± 52.72-17.3 ± 67.06
Week 1316.7 ± 27.0712.1 ± 43.1216.4 ± 26.5346.3 ± 57.2515.9 ± 43.7910.5 ± 28.800.1 ± 46.052.0 ± 83.4416.3 ± 11.93
Week 1613.9 ± 35.4019.6 ± 37.618.3 ± 34.16-2.2 ± 57.329.7 ± 30.170.2 ± 22.0826.6 ± 55.82-31.5 ± 86.974.0 ± 16.21
Week 2014.5 ± 25.7413.2 ± 24.5023.8 ± 26.4910.3 ± 41.3316.4 ± 35.5410.9 ± 29.8138.5 ± 44.11-3.3 ± 52.5840.0 ± 7.07
SecondaryMean Change From Baseline in Iron Concentration

Blood samples were collected from participants at defined time points for the assessment of iron indices, including iron concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Reported as:
Mean · micrograms per deciliter (µg/dL)
Mean Change From Baseline in Iron Concentration
micrograms per deciliter (µg/dL)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Baseline87.4 ± 38.4693.9 ± 36.5690.1 ± 35.0957.7 ± 26.7180.9 ± 36.9473.1 ± 22.2365.7 ± 23.9381.6 ± 37.0158.4 ± 18.77
Week 4-8.0 ± 34.49-11.2 ± 33.59-18.3 ± 22.833.3 ± 35.239.6 ± 29.671.7 ± 23.37-6.6 ± 32.868.6 ± 17.363.8 ± 25.79
Week 8-5.5 ± 45.04-15.0 ± 40.51-8.6 ± 44.304.5 ± 24.06-5.9 ± 36.9111.7 ± 40.33-12.6 ± 26.550.3 ± 11.092.0 ± 20.33
Week 12-2.7 ± 38.24-22.2 ± 43.14-26.0 ± 33.03-2.8 ± 40.49-0.4 ± 40.20-5.1 ± 27.54-16.1 ± 22.88-2.5 ± 43.94-12.6 ± 28.99
Week 16-22.8 ± 39.39-18.3 ± 39.85-17.9 ± 53.89-0.7 ± 10.265.2 ± 30.27-4.6 ± 30.31-13.9 ± 44.0519.5 ± 53.03-12.0 ± 24.06
Week 20-14.2 ± 41.11-9.5 ± 27.87-16.6 ± 46.4928.7 ± 67.73-3.1 ± 32.4313.4 ± 16.03-8.4 ± 28.94-15.3 ± 43.19-10.3 ± 21.57
SecondaryMean Change From Baseline in Ferritin Concentration

Blood samples were collected from participants at defined time points for the assessment of iron indices, including ferritin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Reported as:
Mean · micrograms per liter (µg/L)
Mean Change From Baseline in Ferritin Concentration
micrograms per liter (µg/L)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Baseline939.3 ± 478.641043.6 ± 359.10919.3 ± 298.27910.2 ± 408.03745.2 ± 362.98739.5 ± 329.66723.6 ± 484.291182.2 ± 508.67449.6 ± 423.44
Week 4-30.1 ± 185.45-101.9 ± 204.51-23.7 ± 274.3941.4 ± 335.00152.9 ± 347.9745.5 ± 320.50-145.6 ± 211.1034.8 ± 470.43-61.5 ± 17.37
Week 8-120.8 ± 273.28-185.4 ± 298.1924.9 ± 334.2829.4 ± 361.29-5.6 ± 255.10-87.8 ± 285.30-78.3 ± 254.98111.3 ± 609.61397.8 ± 453.76
Week 12-118.5 ± 220.40-194.8 ± 288.47-42.4 ± 356.19-68.0 ± 275.11-23.8 ± 303.39-30.1 ± 386.24-195.3 ± 304.63-0.5 ± 237.99-35.0 ± 157.46
Week 16-92.0 ± 309.88-70.9 ± 288.3499.5 ± 567.19-144.0 ± 358.7827.8 ± 244.67-97.2 ± 188.15-81.8 ± 447.0180.0 ± 243.2462.3 ± 186.15
Week 20-113.6 ± 327.06-166.6 ± 298.6726.5 ± 497.52-199.4 ± 370.324.8 ± 331.76-51.6 ± 253.07-104.8 ± 347.53249.0 ± 636.33607.0 ± 607.0
SecondaryMean Change From Baseline in Total Iron Binding Capacity

Blood samples were collected from participants at defined time points for the assessment of iron indices, including Total Iron Binding Capacity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Reported as:
Mean · µg/dL
Mean Change From Baseline in Total Iron Binding Capacity
µg/dLLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Baseline237.8 ± 39.28230.7 ± 39.09234.8 ± 44.76210.1 ± 33.33235.7 ± 38.80223.6 ± 34.31218.2 ± 33.80211.0 ± 42.99225.6 ± 98.15
Week 435.9 ± 27.1127.7 ± 33.58-13.4 ± 26.0227.6 ± 28.4941.0 ± 26.2248.2 ± 37.78-0.5 ± 21.4444.2 ± 53.587.8 ± 14.38
Week 830.3 ± 28.4237.0 ± 40.99-1.1 ± 18.3826.3 ± 23.9849.4 ± 27.3458.8 ± 24.54-7.4 ± 19.2656.0 ± 58.15-24.8 ± 58.79
Week 1242.4 ± 27.1037.2 ± 43.09-9.9 ± 25.8525.1 ± 33.9041.0 ± 39.0554.5 ± 44.05-3.8 ± 25.4258.0 ± 14.45-0.6 ± 15.32
Week 1635.0 ± 43.0027.8 ± 35.16-3.0 ± 25.4455.3 ± 28.6353.1 ± 58.3360.9 ± 70.50-13.7 ± 31.4642.5 ± 62.93-2.5 ± 18.52
Week 2038.0 ± 28.1544.9 ± 30.71-9.5 ± 29.2951.7 ± 37.5068.4 ± 43.4067.9 ± 58.44-5.4 ± 29.7866.7 ± 35.22-6.0 ± 21.79
SecondaryMean Change From Baseline in Hepcidin Concentration

Blood samples were collected from participants at defined time points for the assessment of hepcidin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Week 12 and Week 20
Reported as:
Mean · nanograms per milliliter (ng/mL)
Mean Change From Baseline in Hepcidin Concentration
nanograms per milliliter (ng/mL)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Baseline194.870 ± 113.9348208.816 ± 85.1667259.161 ± 134.9995185.852 ± 105.6611215.608 ± 130.7350160.760 ± 102.6261143.519 ± 124.6749239.958 ± 151.385974.748 ± 40.2119
Week 12-50.565 ± 57.6474-53.675 ± 92.1185-66.646 ± 152.3178-55.283 ± 77.1648-34.868 ± 89.7176-74.797 ± 126.1667-62.787 ± 96.1842-128.587 ± 262.6300-1.062 ± 30.4842
Week 20-86.025 ± 100.4382-38.627 ± 75.0555-83.685 ± 95.7049-93.412 ± 115.2839-83.012 ± 98.7521-43.701 ± 80.8411-80.680 ± 125.2481-152.243 ± 218.9284-9.023 ± 80.4001
SecondaryGeometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose

Blood samples were collected from participants at defined time points for the assessment of Cmax of Vadadustat following a single dose.

Time frame:
Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Reported as:
Geometric mean · Micrograms per milliliter (μg/mL)
Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose
Micrograms per milliliter (μg/mL)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgESA Hyporesponder: Vadadustat 600 mg
Week 126.0 ± 87.940.8 ± 54.826.5 ± 59.347.0 ± 38.256.5 ± 39.244.2 ± 73.1
Week 1 +1 (Day 8)20.1 ± 174.437.6 ± 78.923.8 ± 69.044.2 ± 29.660.1 ± 41.631.6 ± 151.6
Week 1128.6 ± 49.324.4 ± 350.632.4 ± 26.938.1 ± 99.041.2 ± 77.7—
Week 13—30.6 ± 102.711.5 ± NA—60.2 ± 9.2—
SecondaryGeometric Mean Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of Vadadustat Following a Single Dose

Blood samples were collected from participants at defined time points for the assessment of AUC and AUC0-24 of Vadadustat following a single dose.

Time frame:
Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Reported as:
Geometric mean · hours*µg/mL
Geometric Mean Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of Vadadustat Following a Single Dose
hours*µg/mLLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgESA Hyporesponder: Vadadustat 600 mg
Week 1338 ± 63.8518 ± 71.1342 ± 81.7605 ± 54.5786 ± 36.6464 ± 80.9
Week 1 +1 (Day 8)289 ± 76.6465 ± 80.8310 ± 94.7566 ± 41.1847 ± 54.8388 ± 112.4
Week 11344 ± 53.5338 ± 282.0402 ± 70.8450 ± 68.2588 ± 52.5—
SecondaryMedian Terminal Half-life (t1/2) of Vadadustat Following a Single Dose

Blood samples were collected from participants at defined time points for the assessment of t1/2 of Vadadustat following a single dose.

Time frame:
Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Reported as:
Median · Hours
Median Terminal Half-life (t1/2) of Vadadustat Following a Single Dose
HoursLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgESA Hyporesponder: Vadadustat 600 mg
Week 18.53 (5.36 to 26.6)10.5 (3.26 to 21.1)12.5 (7.33 to 20.7)10.3 (6.33 to 18.3)11.0 (6.51 to 18.0)9.01 (8.45 to 9.58)
Week 1 +1 (Day 8)8.82 (5.80 to 22.9)8.83 (4.98 to 70.0)10.1 (4.79 to 17.9)12.4 (5.73 to 47.8)14.6 (5.61 to 31.3)11.7 (11.3 to 12.0)
Week 116.73 (3.55 to 22.1)10.4 (6.46 to 13.8)6.49 (3.22 to 9.75)3.95 (3.95 to 3.95)5.65 (5.26 to 7.12)—
Week 13—11.0 (11.0 to 11.0)——5.01 (5.01 to 5.01)—
SecondaryMedian Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose

Blood samples were collected from participants at defined time points for the assessment of Tmax of Vadadustat following a single dose.

Time frame:
Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Reported as:
Median · Hours
Median Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose
HoursLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgESA Hyporesponder: Vadadustat 600 mg
Week 12.08 (0.00 to 11.50)2.72 (1.83 to 5.03)3.48 (1.92 to 10.50)3.50 (1.58 to 9.00)2.00 (1.75 to 5.03)3.28 (1.83 to 4.50)
Week 1 +1 (Day 8)3.28 (1.75 to 6.75)2.11 (0.00 to 5.23)3.33 (1.80 to 5.00)3.30 (0.00 to 5.00)2.17 (1.75 to 5.05)3.42 (1.80 to 4.50)
Week 113.23 (0.00 to 4.50)3.50 (1.75 to 10.83)3.50 (2.00 to 4.67)2.03 (1.75 to 3.63)2.11 (1.80 to 5.00)—
Week 13—1.98 (1.75 to 5.00)4.25 (4.25 to 4.25)—2.04 (1.97 to 2.12)—
SecondaryGeometric Mean Elimination Rate Constant (λz) of Vadadustat Following a Single Dose

Blood samples were collected from participants at defined time points for the assessment of λz of Vadadustat following a single dose.

Time frame:
Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Reported as:
Geometric mean · 1/hour
Geometric Mean Elimination Rate Constant (λz) of Vadadustat Following a Single Dose
1/hourLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgESA Hyporesponder: Vadadustat 600 mg
Week 10.0797 ± 38.70.0665 ± 50.50.0560 ± 41.60.0681 ± 32.70.0608 ± 46.90.0771 ± 8.9
Week 1 +1 (Day 8)0.0720 ± 44.20.0615 ± 70.00.0714 ± 53.90.0469 ± 72.20.0469 ± 74.40.0594 ± 4.5
Week 110.0925 ± 65.50.0687 ± 26.50.124 ± 92.00.175 ± NA0.116 ± 15.9—
Week 13—0.0632 ± NA——0.138 ± NA—
SecondaryGeometric Mean Apparent Total Body Clearance (CLss/F) of Vadadustat Following a Single Dose

Blood samples were collected from participants at defined time points for the assessment of CLss/F of Vadadustat following a single dose.

Time frame:
Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Reported as:
Geometric mean · liters per hour
Geometric Mean Apparent Total Body Clearance (CLss/F) of Vadadustat Following a Single Dose
liters per hourLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgESA Hyporesponder: Vadadustat 600 mg
Week 10.888 ± 63.80.869 ± 71.10.877 ± 81.70.744 ± 54.50.763 ± 36.61.29 ± 80.9
Week 1 +1 (Day 8)1.04 ± 76.60.967 ± 80.80.968 ± 94.70.795 ± 41.10.708 ± 54.81.55 ± 112.4
Week 110.872 ± 53.51.33 ± 282.00.747 ± 70.81.00 ± 68.21.02 ± 52.5—
SecondaryGeometric Mean Apparent Volume of Distribution (Vz/F) of Vadadustat Following a Single Dose

Blood samples were collected from participants at defined time points for the assessment of Vz/F of Vadadustat following a single dose.

Time frame:
Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Reported as:
Geometric mean · Liters
Geometric Mean Apparent Volume of Distribution (Vz/F) of Vadadustat Following a Single Dose
LitersLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgESA Hyporesponder: Vadadustat 600 mg
Week 110.9 ± 36.214.3 ± 53.413.7 ± 69.712.1 ± 38.613.8 ± 16.715.8 ± 56.9
Week 1 +1 (Day 8)12.5 ± 36.613.7 ± 41.017.4 ± 50.415.3 ± 67.415.6 ± 27.212.4 ± 35.8
Week 1110.2 ± 28.710.7 ± 37.610.1 ± 10.38.24 ± NA8.76 ± 18.9—

Adverse events

Collected over Up to Week 24 (from first dose of study drug to last dose + 4 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose of Epoetin Alfa: Vadadustat 300 mg0/34 (0%)9/34 (26.5%)11/34 (32.4%)
Low Dose of Epoetin Alfa: Vadadustat 450 mg0/35 (0%)7/35 (20%)20/35 (57.1%)
Low Dose of Epoetin Alfa: Epoetin Alfa0/23 (0%)5/23 (21.7%)10/23 (43.5%)
High Dose of Epoetin Alfa: Vadadustat 300 mg1/18 (5.6%)8/18 (44.4%)9/18 (50%)
High Dose of Epoetin Alfa: Vadadustat 450 mg1/21 (4.8%)6/21 (28.6%)9/21 (42.9%)
High Dose of Epoetin Alfa: Vadadustat 600 mg1/21 (4.8%)10/21 (47.6%)10/21 (47.6%)
High Dose of Epoetin Alfa: Epoetin Alfa1/13 (7.7%)5/13 (38.5%)8/13 (61.5%)
ESA Hyporesponder: Vadadustat 600 mg0/5 (0%)4/5 (80%)4/5 (80%)
ESA Hyporesponder: Epoetin Alfa0/5 (0%)3/5 (60%)2/5 (40%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
Fluid overloadMetabolism and nutrition disorders0/340/350/230/180/211/211/130/52/5
AnaemiaBlood and lymphatic system disorders0/340/350/230/180/210/210/131/50/5
Gastrointestinal haemorrhageGastrointestinal disorders0/340/350/230/180/210/210/131/51/5
Non-cardiac chest painGeneral disorders0/340/350/230/180/210/210/130/51/5
Liver injuryHepatobiliary disorders0/340/350/230/180/210/210/130/51/5
Staphylococcal bacteraemiaInfections and infestations0/340/350/230/180/210/210/131/50/5
HyperkalaemiaMetabolism and nutrition disorders0/341/350/230/180/211/210/131/50/5
HypoglycaemiaMetabolism and nutrition disorders0/340/350/230/180/210/210/130/51/5
SeizureNervous system disorders0/340/350/230/180/210/210/130/51/5
Pleural effusionRespiratory, thoracic and mediastinal disorders1/340/350/230/180/210/211/130/51/5
Most frequent other events
Showing 10 of 84
Most frequent other events
EventLow Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin Alfa
DiarrhoeaGastrointestinal disorders1/343/354/234/182/214/211/131/50/5
AnaemiaBlood and lymphatic system disorders0/340/350/231/180/211/210/131/50/5
ThrombocytopeniaBlood and lymphatic system disorders0/340/350/230/180/210/210/131/50/5
Bundle branch block rightCardiac disorders0/340/350/230/180/210/210/130/51/5
Sinus tachycardiaCardiac disorders0/340/350/230/180/210/210/131/50/5
TinnitusEar and labyrinth disorders0/340/350/230/180/210/210/131/50/5
NauseaGastrointestinal disorders2/340/350/230/180/210/210/131/50/5
PyrexiaGeneral disorders0/340/350/230/180/210/210/130/51/5
Ulcer haemorrhageGeneral disorders0/340/350/230/180/210/210/131/50/5
AcarodermatitisInfections and infestations0/340/350/230/180/210/210/131/50/5

Baseline characteristics

Age, Customized
Age, Customized(Participants)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin AlfaTotal
<65 years202215111813743113
>=65 years1512873861262
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin AlfaTotal
Female1413477964367
Male212119111412712108
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose of Epoetin Alfa: Vadadustat 300 mgLow Dose of Epoetin Alfa: Vadadustat 450 mgLow Dose of Epoetin Alfa: Epoetin AlfaHigh Dose of Epoetin Alfa: Vadadustat 300 mgHigh Dose of Epoetin Alfa: Vadadustat 450 mgHigh Dose of Epoetin Alfa: Vadadustat 600 mgHigh Dose of Epoetin Alfa: Epoetin AlfaESA Hyporesponder: Vadadustat 600 mgESA Hyporesponder: Epoetin AlfaTotal
American Indian or Alaska Native0102010004
Asian2111111019
Native Hawaiian or Other Pacific Islander1010000024
Black or African American181978131462289
White1091356553056
More than one race0000000000
Unknown or Not Reported44121010013
08

Study locations

41 sites
  • Research Site
    Fresno, California 93720, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Riverside, California 92501, United States
  • Research Site #1
    San Dimas, California 91773, United States
  • Research Site #2
    San Dimas, California 91773, United States
  • Research Site
    San Gabriel, California 91776, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Vacaville, California 95688, United States
  • Research Site
    Victorville, California 92394, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Bridgeport, Connecticut 06606, United States
  • Research Site
    Hartford, Connecticut 06762, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33134, United States
  • Research Site
    Miami, Florida 33150, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Augusta, Georgia 30909, United States
  • Research Site
    Statesboro, Georgia 30458, United States
  • Research Site
    Roseville, Michigan 48066, United States
  • Research Site #1
    Minneapolis, Minnesota 55404, United States
  • Research Site #2
    Minneapolis, Minnesota 55404, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Las Vegas, Nevada 89107, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Research Site
    El Paso, Texas 79915, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    San Antonio, Texas 78258, United States
  • Research Site
    Chesapeake, Virginia 23320, United States
  • Research Site
    Norfolk, Virginia 23510, United States
  • Research Site
    Wauwatosa, Wisconsin 53226, United States
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jun 2020, 16 months.

Results were first posted in Sep 2022, 2 years 3 months after primary completion. A results delay was requested in Jun 2021.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 16 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2018
First posted
Jan 10, 2019
StartActual
Jan 31, 2019
Primary completionActual
Jun 5, 2020
CompletionActual
Jul 15, 2020
Results delay requested
Jun 4, 2021
Results first posted
Sep 29, 2022
Last update
Sep 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03799627
Responsible party
Sponsor
First posted
Jan 10, 2019
Start date
Jan 31, 2019
Primary completion
Jun 5, 2020
Completion
Jul 15, 2020
Results posted
Sep 29, 2022
Last update
Sep 29, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion